Hotta, Katsuyuki
Nishio, Makoto
Saito, Haruhiro
Okamoto, Isamu
Nakahara, Yasuharu
Hayashi, Hidetoshi
Hayama, Manabu
Laud, Peter
Jiang, Haiyi
Paz-Ares, Luis
Azuma, Koichi
Funding for this research was provided by:
AstraZeneca
Article History
Received: 21 August 2020
Accepted: 9 March 2021
First Online: 7 April 2021
Declarations
:
: Katsuyuki Hotta has received research funding from AstraZeneca, Chugai, Eli Lilly, Bristol-Myers Squibb, and Astellas, and lecture fees/honoraria/other fees from MSD and AstraZeneca. Makoto Nishio has received research funding from Chugai, AstraZeneca, Ono, Bristol-Myers Squibb, Pfizer, Eli Lilly, Boehringer Ingelheim, MSD, Novartis, Taiho, Daiichi Sankyo, Merck Serono, and Astellas, and lecture fees/honoraria/other fees from Chugai, AstraZeneca, Ono, Bristol-Myers Squibb, Pfizer, Eli Lilly, Taiho, Boehringer Ingelheim, MSD, Novartis, and Daiichi Sankyo. Haruhiro Saito has received research funding from Chugai and AstraZeneca. Isamu Okamoto has received research funding from Bristol-Myers Squibb, Chugai, AstraZeneca, Boehringer Ingelheim, AbbVie, Daiichi Sankyo, Taiho, and Ono, lecture fees/honoraria/other fees from Eli Lilly, Chugai, AstraZeneca, MSD, and Pfizer, and scholarship (incentive) endowments from Eli Lilly, Chugai, Boehringer Ingelheim, Taiho, and Ono. Hidetoshi Hayashi has received research funding from AstraZeneca, Boehringer Ingelheim, Ono, and Chugai, and lecture fees/honoraria/other fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eli Lilly, Kyorin, MSD, Ono, Pfizer, and Taiho. Manabu Hayama and Haiyi Jiang are full-time employees of AstraZeneca. Peter Laud is contracted to AstraZeneca from the Statistical Services Unit at the University of Sheffield, which received funding from AstraZeneca. Luis Paz-Ares has received research funding from Bristol-Myers Squibb and AstraZeneca, and lecture fees/honoraria/other fees from MSD, AstraZeneca, Roche, Bristol-Myers Squibb, and Eli Lilly. Koichi Azuma has received research funding from AstraZeneca, MSD, Bristol-Myers Squibb, Ono, and Chugai, and lecture fees/honoraria/other fees from AstraZeneca, MSD, Bristol-Myers Squibb, Ono, and Chugai. Yasuharu Nakahara has no conflicts of interest to declare.